"&#xa0;\nWritten Evidence submitted by Dr Roland Salmon (CJD0002)What do you consider to be the likely prevalence of subclinical vCJD infection in the UK population? What evidence is there to support this view?&#xa0;\nHow might this subclinical infection rate translate to future cases of vCJD? What are the key uncertainties in the relationship between subclinical and clinical vCJD?&#xa0;\n&#xa0;\nWhat are the likely routes of infection for vCJD? How have the potential modes of transmission changed over time?&#xa0;\n&#xa0;\n&#xa0;\nWhat procedures are currently in place to monitor, control and prevent further spread of vCJD across the UK population? What more could be done to reduce the risk posed by vCJD?&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nOther considerations&#xa0;\n&#xa0;\nReferences&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nDeclaration of interestI am currently Board Member for Wales and Chair of the Welsh Food Advisory Committee for the Food Standards Agency and also a member of the Department of Health’s Advisory Committee on Dangerous Pathogens and of t\nhat committee’s Spongiform Encephalopathy Sub Group.  I am a member of the \nConseil\n \nd’Administration\n (Management Advisory Board) of the \nInstitut\n de \nVeille\n \nSanitaire\n (French National Institute for Public Health Surveillance).\n&#xa0;\nNovember 2013\n&#xa0;\n"